{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:35:47Z","timestamp":1784846147910,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03249-w","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:53:49Z","timestamp":1750132429000},"page":"3922-3944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries"],"prefix":"10.1007","volume":"42","author":[{"given":"Marjorie","family":"Argollo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon K.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo C.","family":"Balderramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9320-4824","authenticated-orcid":false,"given":"Olga","family":"Fadeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenore","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"10401","key":"3249_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571\u201384.","journal-title":"Lancet"},{"issue":"10080","key":"3249_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet. 2017;389(10080):1741\u201355.","journal-title":"Lancet"},{"issue":"2","key":"3249_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","volume":"17","author":"E Louis","year":"2023","unstructured":"Louis E, Siegel CA, James B, Heidenreich S, Krucien N, Ghosh S. Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD study]. J Crohns Colitis. 2023;17(2):231\u20139.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3249_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1574886316666211109092354","volume":"17","author":"S Athimni","year":"2022","unstructured":"Athimni S, Slouma M, Dhahri R, Gharsallah I, Metoui L, Louzir B. Tuberculosis infection under anti-TNF alpha treatment. Curr Drug Saf. 2022;17(3):235\u201340.","journal-title":"Curr Drug Saf"},{"issue":"5","key":"3249_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/ibd\/izy313","volume":"25","author":"B Click","year":"2019","unstructured":"Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis. 2019;25(5):831\u201342.","journal-title":"Inflamm Bowel Dis"},{"key":"3249_CR6","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 27 Apr 2024."},{"issue":"4","key":"3249_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","volume":"161","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY). Gastroenterology. 2021;161(4):1156-67.e3.","journal-title":"Gastroenterology"},{"issue":"13","key":"3249_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"3249_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease. N Engl J Med. 2024;391(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"3249_CR10","doi-asserted-by":"publisher","first-page":"S001","DOI":"10.1093\/ecco-jcc\/jjab075.001","volume":"15","author":"P Irving","year":"2021","unstructured":"Irving P, Sands B, Hoops T, et al. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn\u2019s disease: the SEAVUE study. J Crohns Colitis. 2021;15:S001-S2.","journal-title":"J Crohns Colitis"},{"issue":"10342","key":"3249_CR11","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase\u00a03b trial. Lancet. 2022;399(10342):2200\u201311.","journal-title":"Lancet"},{"issue":"9","key":"3249_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/17474124.2021.1898944","volume":"15","author":"D Denesh","year":"2021","unstructured":"Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol. 2021;15(9):1091\u20136.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10340","key":"3249_CR13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase\u00a03 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031\u201346.","journal-title":"Lancet"},{"issue":"5","key":"3249_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S, et al. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase\u00a03 trials (LIBERTY). Gastroenterology. 2024;167(5):919\u201333.","journal-title":"Gastroenterology"},{"issue":"5","key":"3249_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/apt.17622","volume":"58","author":"A Dignass","year":"2023","unstructured":"Dignass A, Rath S, Kleindienst T, Stallmach A. Review article: translating STRIDE-II into clinical reality\u2014opportunities and challenges. Aliment Pharmacol Ther. 2023;58(5):492\u2013502.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3249_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"3","key":"3249_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/bmjebm-2023-112374","volume":"29","author":"N Joseph-Williams","year":"2024","unstructured":"Joseph-Williams N, Elwyn G, Edwards A. Twenty-one years of the international shared decision making conference: lessons learnt and future priorities. BMJ Evid Based Med. 2024;29(3):151\u20135.","journal-title":"BMJ Evid Based Med"},{"key":"3249_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5146","volume":"341","author":"G Elwyn","year":"2010","unstructured":"Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing shared decision making in the NHS. BMJ. 2010;341:c5146.","journal-title":"BMJ"},{"issue":"9","key":"3249_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","volume":"366","author":"MJ Barry","year":"2012","unstructured":"Barry MJ, Edgman-Levitan S. Shared decision making\u2013pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780\u20131.","journal-title":"N Engl J Med"},{"issue":"6","key":"3249_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.gastrohep.2014.09.003","volume":"38","author":"I Catalan-Serra","year":"2015","unstructured":"Catalan-Serra I, Huguet-Malaves JM, Minguez M, et al. Information resources used by patients with inflammatory bowel disease: satisfaction, expectations and information gaps. Gastroenterol Hepatol. 2015;38(6):355\u201363.","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"3249_CR21","first-page":"671","volume":"24","author":"S Promislow","year":"2010","unstructured":"Promislow S, Walker JR, Taheri M, Bernstein CN. How well does the internet answer patients\u2019 questions about inflammatory bowel disease? Can J Gastroenterol. 2010;24(11):671\u20137.","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"3249_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health"},{"issue":"2","key":"3249_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.rdc.2018.01.009","volume":"44","author":"GS Hazlewood","year":"2018","unstructured":"Hazlewood GS. Measuring patient preferences: an overview of methods with a focus on discrete choice experiments. Rheum Dis Clin N Am. 2018;44(2):337\u201347.","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"3249_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/ajg.2017.470","volume":"113","author":"CV Almario","year":"2018","unstructured":"Almario CV, Keller MS, Chen M, et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol. 2018;113(1):58\u201371.","journal-title":"Am J Gastroenterol"},{"key":"3249_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/CEG.S206970","volume":"12","author":"M Boeri","year":"2019","unstructured":"Boeri M, Myers K, Ervin C, et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol. 2019;12:263\u201378.","journal-title":"Clin Exp Gastroenterol"},{"key":"3249_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/PPA.S152872","volume":"12","author":"JC Gregor","year":"2018","unstructured":"Gregor JC, Williamson M, Dajnowiec D, Sattin B, Sabot E, Salh B. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adher. 2018;12:505\u201313.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"3249_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227635","volume":"15","author":"GS Hazlewood","year":"2020","unstructured":"Hazlewood GS, Pokharel G, Deardon R, et al. Patient preferences for maintenance therapy in Crohn\u2019s disease: a discrete-choice experiment. PLoS ONE. 2020;15(1):e0227635.","journal-title":"PLoS ONE"},{"issue":"5","key":"3249_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/03007995.2020.1716704","volume":"36","author":"LM Hagelund","year":"2020","unstructured":"Hagelund LM, Elkjaer Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin. 2020;36(5):771\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3249_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/11595390-000000000-00000","volume":"5","author":"P Hodgkins","year":"2012","unstructured":"Hodgkins P, Swinburn P, Solomon D, Yen L, Dewilde S, Lloyd A. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient. 2012;5(1):33\u201344.","journal-title":"Patient"},{"issue":"6","key":"3249_CR30","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s12325-022-02143-z","volume":"39","author":"S Schubert","year":"2022","unstructured":"Schubert S, Picker N, Cavlar T, Knop J, Kahraman A, Mohl W. Inflammatory bowel disease patients\u2019 treatment preferences using a discrete choice experiment technique: the InPuT study. Adv Ther. 2022;39(6):2889\u2013905.","journal-title":"Adv Ther"},{"issue":"7","key":"3249_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/00365521.2022.2036808","volume":"57","author":"N Wickramasekera","year":"2022","unstructured":"Wickramasekera N, Coates E, Barr A, et al. Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment. Scand J Gastroenterol. 2022;57(7):797\u2013806.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"3249_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee ISoP","year":"2016","unstructured":"Public Policy Committee ISoP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3249_CR33","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1016\/j.jval.2020.04.393","volume":"23","author":"S Schubert","year":"2020","unstructured":"Schubert S, Knop J, Picker N, Wilke T. PGI39 Inflammatory bowel disease patient\u2019s treatment preferences-using qualitative patient survey data to develop a discrete choice experiment. Value Health. 2020;23:S150.","journal-title":"Value Health"},{"key":"3249_CR34","unstructured":"Johnson RM, Orme BK. A new approach to adaptive CBC. Sawtooth software conference: Citeseer; 2007. p. 85."},{"issue":"7","key":"3249_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18256","volume":"9","author":"AS Alamri","year":"2023","unstructured":"Alamri AS, Georgiou S, Stylianou S. Discrete choice experiments: an overview on constructing D-optimal and near-optimal choice sets. Heliyon. 2023;9(7):e18256.","journal-title":"Heliyon"},{"key":"3249_CR36","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"BK Orme","year":"2005","unstructured":"Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. 1st ed. California: Research Publishers; 2005.","edition":"1"},{"key":"3249_CR37","doi-asserted-by":"crossref","unstructured":"Fiorino G, Bent-Ennakhil N, Varriale P, Braegger F, Hoefkens E. Patient preferences for treatment attributes in inflammatory bowel disease: results from a large survey across seven european countries using a discrete choice experiment. Inflamm Bowel Dis. 2024;30(12):2380\u201394.","DOI":"10.1093\/ibd\/izae015"},{"key":"3249_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-10-1","volume":"10","author":"PB Allen","year":"2010","unstructured":"Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010;10:1.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"3249_CR39","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ibd\/izy015","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Keefer L, Wilding H, Hewitt C, Graff LA, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm Bowel Dis. 2018;24(5):966\u201376.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3249_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/flgastro-2019-101355","volume":"12","author":"SJ Radford","year":"2021","unstructured":"Radford SJ, McGing J, Czuber-Dochan W, Moran G. Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. Frontline Gastroenterol. 2021;12(1):11\u201321.","journal-title":"Frontline Gastroenterol"},{"issue":"2","key":"3249_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ecco-jcc\/jjw145","volume":"11","author":"N Williet","year":"2017","unstructured":"Williet N, Sarter H, Gower-Rousseau C, et al. Patient-reported outcomes in a French nationwide survey of inflammatory bowel disease patients. J Crohns Colitis. 2017;11(2):165\u201374.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"3249_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1177\/1359105312459094","volume":"18","author":"TL Rochelle","year":"2013","unstructured":"Rochelle TL, Fidler H. The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn\u2019s disease. J Health Psychol. 2013;18(7):972\u201383.","journal-title":"J Health Psychol"},{"issue":"12","key":"3249_CR43","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","volume":"25","author":"DR Berg","year":"2019","unstructured":"Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(12):1896\u2013905.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"3249_CR44","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cgh.2013.08.026","volume":"12","author":"GW Moran","year":"2014","unstructured":"Moran GW, Dubeau MF, Kaplan GG, et al. Phenotypic features of Crohn\u2019s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2014;12(3):434-42.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"3249_CR45","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.cgh.2018.12.040","volume":"17","author":"DM Faleck","year":"2019","unstructured":"Faleck DM, Winters A, Chablaney S, et al. Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn\u2019s disease but not ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(12):2497-505.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3249_CR46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","volume":"40","author":"JE Brady","year":"2018","unstructured":"Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509-21.e5.","journal-title":"Clin Ther"},{"key":"3249_CR47","doi-asserted-by":"crossref","unstructured":"Olivera PA, Balderramo D, Lasa JS, et al. Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: data from the RISE-AR study. Gastroenterol Hepatol. 2024:502287.","DOI":"10.1016\/j.gastrohep.2024.502287"},{"issue":"23","key":"3249_CR48","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.3748\/wjg.v27.i23.3396","volume":"27","author":"LY Sassaki","year":"2021","unstructured":"Sassaki LY, Miszputen SJ, Kaiser Junior RL, et al. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol. 2021;27(23):3396\u2013412.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"3249_CR49","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/ibd\/izac269","volume":"29","author":"WC Lin","year":"2023","unstructured":"Lin WC, Tai WC, Chang CH, et al. Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in Taiwan: a prospective nationwide registry (VIOLET) Study. Inflamm Bowel Dis. 2023;29(11):1730\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"3249_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"15","key":"3249_CR51","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"3249_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.therap.2016.11.058","volume":"72","author":"S Ravoire","year":"2017","unstructured":"Ravoire S, Lang M, Perrin E. Advantages and limitations of online communities of patients for research on health products. Therapie. 2017;72(1):135\u201343.","journal-title":"Therapie"},{"issue":"100","key":"3249_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.socscimed.2014.05.026","volume":"114","author":"N Bansback","year":"2014","unstructured":"Bansback N, Hole AR, Mulhern B, Tsuchiya A. Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues. Soc Sci Med. 2014;114(100):38\u201348.","journal-title":"Soc Sci Med"},{"issue":"8","key":"3249_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26(8):661\u201377.","journal-title":"Pharmacoeconomics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03249-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03249-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03249-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:18:00Z","timestamp":1757197080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03249-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3249"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03249-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marjorie Argollo served as a speaker, consultant and advisory board member for AbbVie, Janssen, Takeda and Pfizer. Yoon K. An has received consulting fees and speaker fees from AbbVie, Bristol Myers Squibb (BMS), Eli Lilly, Dr Falk, Ferring, GlaxoSmithKline, Janssen, Pfizer, Samsung, Sandoz, Shire and Takeda Pharmaceuticals; advisory board fees from AbbVie, BMS, Chiesi, Janssen, Microba, NPS Medicine Wise, the Council of Therapeutic Advisory Group (CATAG) and Takeda Pharmaceuticals; and research and educational support from AbbVie, BMS, Cannon, Celltrion, Chiesi, Dr Falk, Ferring, Janssen, Pfizer, Samsung, Sandoz, Siemens and Takeda Pharmaceuticals. Nahla Azzam served on advisory boards and received speaker fees and\/or consultation fees from AbbVie, Takeda, Janssen, Ferring, Falk, Sandoz, Hikma, Pfizer, BMS and Organon; Dr. Azzam has received research funding from Pfizer and AbbVie. Dr Domingo C. Balderramo reports speaker fees from AbbVie, Takeda and Janssen and consulting fees from AbbVie, Takeda, Janssen, Pfizer and Amgen. Olga Fadeeva is an employee of Takeda Pharmaceuticals International AG, Singapore, and holds Takeda stock. Chia-Jung Kuo has no conflicts to disclose. Julie Laurent is an employee of Else Care (Carenity) who received funding to conduct the present study. Elenore Uy is an employee of Takeda Pharmaceuticals International AG, Singapore, and holds Takeda and AbbVie stocks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in accordance with the study protocol, the current version of the Declaration of Helsinki, the International Society of Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices [], any local regulations and the General Data Protection Regulation. As EC submission is mandatory for any survey involving human participants in Brazil, the protocol was reviewed and approved by the Brazil local ethics committee (EC; CEP, Comit\u00eas de \u00c9tica em Pesquisa) and the National EC (CONEP, Comiss\u00e3o Nacional de \u00c9tica em Pesquisa), Certificate of Presentation for Ethical Consideration (Certificado de Apresenta\u00e7\u00e3o para \u00c9tica em Pesquisa), CAAE 66895823.5.0000.5487. Before participating in the study, all patients completed an informed consent form that was translated into the language of the questionnaire. Survey respondents were compensated for their participation. The value and mode of compensation varied depending on local regulations and the time required to complete the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}